[Form 4] Vertex Pharmaceuticals Inc Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

4

Rhea-AI Filing Summary

Analyzing...

07/17/2025 - 04:09 PM

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Vertex Pharmaceuticals Inc

NASDAQ:VRTX

VRTX Rankings

#127 Ranked by Market Cap

N/A Ranked by Dividends

VRTX Latest News

Jul 14, 2025

Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

Jul 14, 2025

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain

Jul 8, 2025

Vertex to Announce Second Quarter 2025 Financial Results on August 4th

Jul 1, 2025

Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

Jun 23, 2025

Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea

VRTX Latest SEC Filings

Jul 17, 2025

[Form 4] Vertex Pharmaceuticals Inc Insider Trading Activity

Jul 2, 2025

[Form 3] Vertex Pharmaceuticals Inc Initial Statement of Beneficial Ownership

Jul 2, 2025

[Form 4] Vertex Pharmaceuticals Inc Insider Trading Activity

VRTX Stock Data

Market Cap 123.14B

Float 256.18M

Insiders Ownership 0.11%

Institutions Ownership 96.65%

Short Percent 2.14%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City BOSTON